10 completed, 8 unknown, 1 not yet recruiting, 1 recruiting. 10 Phase 2, 4 Phase 1, 4 Phase 3, 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Unknown 6, Completed 3, Terminated 1 |
| Phase 1 | 4 | Unknown 3, Completed 1 |
| Phase 3 | 4 | Completed 4 |
| Phase 4 | 3 | Completed 1, Not yet recruiting 1, Unknown 1 |
Follow SciClone Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer Breast Cancer Metastatic, HR+/HER2- Advanced Breast Cancer | Withdrawn | SciClone Pharmaceuticals | 2025-08-01 | 2025-11-28 | ||
| Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer Endocrine therapy, Chemotherapy Prednisone - ESR1 Gene Mutation, Advanced Breast Cancer | Recruiting | SciClone Pharmaceuticals | 450 | 2024-08-08 | 2024-08-12 | |
| Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC ELacestrant - ESR1 Gene Mutation, Advanced Breast Cancer | Unknown | SciClone Pharmaceuticals | 350 | 2024-07-13 | 2024-08-09 | |
| Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. Naxitamab - Neuroblastoma | Phase 4 | Not yet recruiting | SciClone Pharmaceuticals | 62 | 2023-10-31 | 2023-09-21 |
| Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor - Advanced Solid Tumor, Refractory Tumor | Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 60 | 2023-04-01 | 2023-03-30 |
| PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors PT-112 - Biliary Tract Cancer | Phase 1 / Phase 2 | Unknown | SciClone Pharmaceuticals | 68 | 2020-04-13 | 2022-05-02 |
| An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma PT-112 Injection - Advanced Solid Tumors | Phase 1 / Phase 2 | Unknown | SciClone Pharmaceuticals | 125 | 2018-03-07 | 2018-03-16 |
| First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy Thymalfasin (Thymosin alpha 1, Ta1), SoC (tyrosine kinase inhibitor) - EGFR Mutation Positive Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | SciClone Pharmaceuticals | 188 | 2016-10-01 | 2016-09-19 |
| The Efficacy and Safety of Ta1 for Sepsis Thymosin alpha 1, Placebo - Sepsis | Phase 3 | Completed | Sun Yat-sen University | 1106 | 2016-09-06 | 2023-04-10 |
| Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type Thymalfasin (Thymosin alpha 1, Ta1), SoC (chemotherapy and platinum agent) - Non-Small Cell Lung Cancer | Phase 2 | Unknown | SciClone Pharmaceuticals | 140 | 2016-09-01 | 2016-09-19 |
| Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection curative resection, thymalfasin, nucleoside analog (suggest to use entecavir) - Curable Hepatitis B Virus-Related Hepatocellular Carcinoma | Phase 4 | Unknown | Jia Fan | 360 | 2015-01-01 | 2014-11-21 |
| Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer SCV-07, Placebo - Oral Mucositis | Phase 2 | Unknown | SciClone Pharmaceuticals | 160 | 2010-12-01 | 2014-05-26 |
| Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV SCV-07 - Chronic Hepatitis C | Completed | SciClone Pharmaceuticals | 12 | 2010-08-01 | 2012-03-08 | |
| Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed SCV-07 - Chronic Hepatitis C | Phase 2 | Completed | SciClone Pharmaceuticals | 40 | 2009-09-01 | 2012-06-08 |
| Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer Placebo, SCV-07 - Oral Mucositis, Head and Neck Cancer | Phase 2 | Completed | SciClone Pharmaceuticals | 59 | 2008-09-01 | 2009-11-23 |
| Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine RP101, Gemcitabine (1000 mg/m2) - Pancreatic Cancer | Phase 2 | Terminated | SciClone Pharmaceuticals | 153 | 2007-09-01 | 2011-06-08 |
| Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B Pegylated Interferon-alpha2a, Thymosin alpha1 & Pegylated Interferon-alpha2a - Chronic Hepatitis B | Phase 4 | Completed | Seoul National University Hospital | 52 | 2005-12-01 | 2011-07-21 |
| Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin. Thymosin alpha 1, Ribavirin, PEGinterferon alfa2a - Chronic Hepatitis C | Phase 3 | Completed | sigma-tau i.f.r. S.p.A. | 552 | 2004-12-01 | 2010-08-10 |
| Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin thymalfasin (thymosin alpha 1), PEGinterferon alfa-2a - Hepatitis C, Hepatitis C, Chronic | Phase 3 | Completed | SciClone Pharmaceuticals | 500 | 2002-05-01 | 2008-01-15 |
| Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a, placebo + PEGinterferon alfa-2a - Hepatitis C, Hepatitis C, Chronic | Phase 3 | Completed | SciClone Pharmaceuticals | 500 | 2002-04-01 | 2008-01-15 |
Showing 20 of 22. Sign in to see all of them.
Hepatitis C, Chronic (5) · Hepatitis C (3) · Carcinoma, Non-Small-Cell Lung (2) · Head and Neck Neoplasms (2) · Neoplasms (2) · Stomatitis (2) · Biliary Tract Neoplasms (1) · Carcinoma, Hepatocellular (1) · Cystic Fibrosis (1) · Digestive System Diseases (1) · Gastroenteritis (1) · Gastrointestinal Diseases (1) · Genetic Diseases, Inborn (1) · Hepatitis B, Chronic (1) · Liver Cirrhosis (1)
Thymalfasin (10) · golotimod (4) · peginterferon alfa-2a (4) · Gemcitabine (2) · Granulocyte-Macrophage Colony-Stimulating Factor (2) · Trace amine-associated receptor 1 (2) · Afatinib (1) · Carboplatin (1) · Cisplatin (1) · Drug Therapy (1) · Erlotinib Hydrochloride (1) · Gefitinib (1) · Immune Checkpoint Inhibitors (1) · Injections (1) · Isotretinoin (1)
China (8) · United States (8) · Italy (3) · France (2) · Germany (2) · Puerto Rico (2) · Spain (2) · Argentina (1) · Brazil (1) · Chile (1) · Greece (1) · Hungary (1) · Netherlands (1) · Peru (1) · Poland (1)
Israel Rios, MD (2) · Eduardo Martins (1) · Guan Xiangdong, M. D (1) · Jianli Zhao, Doctor (1) · Jin Li, MD (1) · Jung H Yoon, M.D. (1) · Katharina Modelska, MD (1) · Manuel Hidalgo, MD, PhD (1) · Mario Rizzetto, MD (1) · Prof. Paolo Marchetti, MD (1) · Qing Qu, Doctor (1) · Tianshu Liu, M.D. (1)
PMID 17495242, PMID 20549321, PMID 21833720, PMID 22233415, PMID 23045964, PMID 23327199, PMID 26094695, PMID 26096650, PMID 26632544, PMID 33331662, PMID 35870709, PMID 35874780, PMID 37983082, PMID 38458816, PMID 39814420, PMID 3998766, PMID 42164588
2004 (1)